Mario P. Colombo

Via Venezian 1
Milan, 20133, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 148 publications

ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness.

ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 01, 2026

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Journal: Clinical lung cancer

Published: January 11, 2026

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 29, 2025

ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs.

ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 12, 2025

Neutrophil extracellular traps in cancer: immune modulation, therapy resistance, and the dilemma of targeting.

Neutrophil extracellular traps in cancer: immune modulation, therapy resistance, and the dilemma of targeting.

Journal: Cell death & disease

Published: February 14, 2025

EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.

EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.

Journal: Epigenomics

Published: January 29, 2025

Extraction of a stromal metastatic gene signature in breast cancer via spatial profiling.

Extraction of a stromal metastatic gene signature in breast cancer via spatial profiling.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 13, 2024

Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone.

Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone.

Journal: The Journal of clinical investigation

Published: September 30, 2024

Mast cell heparanase promotes breast cancer stem-like features via MUC1/estrogen receptor axis.

Mast cell heparanase promotes breast cancer stem-like features via MUC1/estrogen receptor axis.

Journal: Cell death & disease

Published: May 28, 2024

Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.

Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.

Journal: Research square

Published: April 02, 2024

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 27, 2024

Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response.

Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response.

Journal: Epigenomics

Published: March 26, 2024

Showing 1-12 of 148

Last Updated: 09/26/2026